These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9819592)

  • 1. [Can aminopenicillin be prescribed as monotherapy in case of community-acquired pneumonia?].
    Léophonte P
    Presse Med; 1998 Oct; 27(31):1580-1. PubMed ID: 9819592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone.
    Rosón B; Carratalà J; Tubau F; Dorca J; Liñares J; Pallares R; Manresa F; Gudiol F
    Microb Drug Resist; 2001; 7(1):85-96. PubMed ID: 11310807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.
    Feldman C
    J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Would ampicillin alone again be enough for treating community-acquired pneumonias?].
    Bédos JP
    Presse Med; 1998 Sep; 27(28):1440-1. PubMed ID: 9793046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elderly patients with community-acquired pneumonia: optimal treatment strategies.
    Thiem U; Heppner HJ; Pientka L
    Drugs Aging; 2011 Jul; 28(7):519-37. PubMed ID: 21721597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale for treating community-acquired lower respiratory tract infections with amoxicillin/sulbactam combination through pharmacodynamic analysis in the setting of aminopenicillin-resistant organisms.
    Bantar C; Nicola F; Fernandez Canigia L; Arenoso HJ; Soutric J; Montoto M; Blanco M; Smayevsky J; Jasovich A
    J Chemother; 2001 Aug; 13(4):402-6. PubMed ID: 11589483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Penicillin-resistant pneumococci and the empirical use of penicillins in the treatment of community-acquired acute pneumonia].
    Sánchez C; Armengol R; Mir I; Lite J; Garau J
    Enferm Infecc Microbiol Clin; 1992; 10(6):334-9. PubMed ID: 1391015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Urinary pneumococcal or Legionella antigen detection tests and low-spectrum antibiotic therapy for community-acquired pneumonia].
    Roger PM; Risso K; Hyvernat H; Landraud L; Vassallo M; Dellamonica J; de Salvador F; Cua E; Bernardin G
    Med Mal Infect; 2010 Jun; 40(6):347-51. PubMed ID: 20172672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumococcal antimicrobial resistance: therapeutic strategy and management in community-acquired pneumonia.
    Aspa J; Rajas O; de Castro FR
    Expert Opin Pharmacother; 2008 Feb; 9(2):229-41. PubMed ID: 18201146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia.
    Weiss K; Tillotson GS
    Chest; 2005 Aug; 128(2):940-6. PubMed ID: 16100190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children.
    Kogan R; Martínez MA; Rubilar L; Payá E; Quevedo I; Puppo H; Girardi G; Castro-Rodriguez JA
    Pediatr Pulmonol; 2003 Feb; 35(2):91-8. PubMed ID: 12526069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftaroline fosamil for treatment of community-acquired pneumonia: findings from FOCUS 1 and 2 and potential role in therapy.
    DiMondi VP; Drew RH; Chen LF
    Expert Rev Anti Infect Ther; 2011 Aug; 9(8):567-72. PubMed ID: 21819323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010].
    Wang H; Liu YL; Chen MJ; Xu YC; Sun HL; Yang QW; Hu YJ; Cao B; Chu YZ; Liu Y; Zhang R; Yu YS; Sun ZY; Zhuo C; Ni YX; Hu BJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin.
    Appelbaum PC; Gillespie SH; Burley CJ; Tillotson GS
    Int J Antimicrob Agents; 2004 Jun; 23(6):533-46. PubMed ID: 15194123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Community-acquired pneumonia in children: importance of Mycoplasma pneumoniae infections and efficacy of antibiotics].
    Gendrel D; Raymond J; Moulin F; Iniguez JL; Truong M; Ravilly S; Chaussain M; Lebon P; Kalifa G
    Presse Med; 1996 May; 25(17):793-7. PubMed ID: 8762275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Penicillin resistance not a factor in outcome from invasive Streptococcus pneumoniae community-acquired pneumonia in adults when appropriate empiric therapy is started.
    Mufson MA; Chan G; Stanek RJ
    Am J Med Sci; 2007 Mar; 333(3):161-7. PubMed ID: 17496734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.
    Garin N; Genné D; Carballo S; Chuard C; Eich G; Hugli O; Lamy O; Nendaz M; Petignat PA; Perneger T; Rutschmann O; Seravalli L; Harbarth S; Perrier A
    JAMA Intern Med; 2014 Dec; 174(12):1894-901. PubMed ID: 25286173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of community-acquired pneumonia--treatment].
    Andersen LV; Brock B; Jakobsen P; Nielsen LP
    Ugeskr Laeger; 2008 Jan; 170(3):127-30. PubMed ID: 18208726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
    Siquier B; Sánchez-Alvarez J; García-Mendez E; Sabriá M; Santos J; Pallarés R; Twynholm M; Dal-Ré R;
    J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.